|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 15, 2017 ) Prostate cancer is the cancer of prostate gland. According to CDC, it is one of the leading cause of cancer death in men across the races in the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. About one in 35 men die due to prostate cancer. Growth in the prostate can be benign or malignant. Prostate cancer cells spread by breaking away from a prostate tumor. They may travel through blood vessels or lymph vessels and reach other parts of the body. The cells that spread might bind to other tissues, form new tumors, and sometimes damage those tissues as well. When prostate cancer cells spread from their original place to another, the new tumor formed also has the same kind of abnormal cells.
Publisher's analysts forecast the global prostate cancer drugs market to grow at a CAGR of 9.21% during the period 2016-2020.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001497965/sample
Covered in this report
The report covers the present scenario and the growth prospects of the global prostate cancer drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
-Americas
-APAC
-EMEA
Publisher's report, Global Prostate Cancer Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
-AbbVie
-Astellas Pharma
-AstraZeneca
-Johnson & Johnson
-Sanofi
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001497965/buying
Other prominent vendors
-Active Biotech
-ADC Therapeutics
- Advantagene
- Advaxis Pharmaceuticals
- ANI Pharmaceuticals
- ArQule
- Athenex Pharmaceuticals
- Bavarian Nordic
- Bayer HealthCare
- BHR Pharma
- BMS
- Boehringer Ingelheim
- Camurus
- Cleveland BioLabs
- CureVac
- Dendreon
- Dextech Medical
- Eisai
- Endo Pharmaceuticals
- Ferring Pharmaceutical
- Foresee Pharmaceuticals
- GlaxoSmithKline
- GTx
-Innocrin Pharmaceutical
- Inspyr Therapeutics
- Io Therapeutics
- Lidds AB
- Merck Group
- Myovant Sciences
- Northwest Biotherapeutics
- Novartis
- Nymox Pharmaceuticals
- OncoGenex
- Oncolytics Biotech
- Orion
- Pharmamar
- Progenics Pharmaceuticals
- Sotio
-Spectrum Pharmaceuticals
- Synta
- Takeda Pharmaceuticals
- Teva Pharmaceutical
-Tokai Pharmaceuticals
Market driver
-Physicians preference toward adopting hormonal therapies
-For a full, detailed list, view our report
Market challenge
-Presence of alternative treatment approaches
-For a full, detailed list, view our report
Market trend
-Emergence of targeted therapies and immunotherapies
-For a full, detailed list, view our report
For more information about this report: http://www.reportsweb.com/global-prostate-cancer-drugs-market-2016-2020
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
